Pfizer Inc. $PFE Shares Sold by HF Advisory Group LLC

HF Advisory Group LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 18.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 122,370 shares of the biopharmaceutical company’s stock after selling 26,981 shares during the period. HF Advisory Group LLC’s holdings in Pfizer were worth $3,047,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Horizon Financial Services LLC lifted its holdings in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the last quarter. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer in the 3rd quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $30,000. Darwin Wealth Management LLC bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $32,000. Finally, True Wealth Design LLC lifted its stake in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Guggenheim raised their target price on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. UBS Group assumed coverage on Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective for the company. Bank of America reduced their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Barclays assumed coverage on Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.19.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong technical and earnings backdrop: analysts point to PFE trading above its 50- and 200-day SMAs for months and the company recently beat quarterly EPS and revenue estimates, supporting momentum and investor confidence. PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play
• Positive Sentiment: Large, near-term revenue recognition: a Belgian court ordered Poland and Romania to accept roughly €1.9bn (~$2.2bn) of Pfizer-made COVID vaccines, which should support near-term sales and cash flow visibility. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: Oncology and pipeline optimism: coverage notes that recent oncology wins and pipeline bets are supporting sentiment despite a flat 2026 outlook, giving investors a growth narrative beyond legacy vaccines. Pfizer Stock Edges Higher as Oncology Wins and Pipeline Bets Fuel Optimism Amid Flat 2026 Outlook
• Neutral Sentiment: Strategic reshaping of assets: Pfizer has exited its ViiV HIV JV stake as partners reshape ownership — this alters future royalty/earnings mix but is not an immediate revenue shock. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Operational adjustments: reports that Pfizer will close its South San Francisco research site suggest cost/portfolio realignment — could trim R&D footprint while freeing resources for higher-priority programs. Pfizer is said to close South San Francisco research site
• Negative Sentiment: Recruitment problems stall a major US COVID vaccine trial: Pfizer and BioNTech paused enrollment for a large U.S. trial in adults 50–64 due to low recruitment, which could delay or limit incremental vaccine approvals and future COVID franchise growth. Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Analyst skepticism on growth: a bearish take argues Pfizer’s large dividend may mask underlying growth challenges, which could cap multiple expansion if revenues slow. Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem

Pfizer Stock Performance

Pfizer stock opened at $28.56 on Thursday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $28.64. The firm’s 50 day simple moving average is $26.99 and its 200-day simple moving average is $25.77. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The company has a market cap of $162.41 billion, a P/E ratio of 21.00 and a beta of 0.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.